Health

STAT+: PepGen says early trial for muscular dystrophy drug looks promising

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 12:06:24 UTC.

Briefings

PepGen reported Tuesday that its experimental drug showed the most promising early data in the race to treat myotonic dystrophy type 1 (DM1), a condition affecting over 100,000 people in the U.S. and Europe. The data came from six patients treated for 12 weeks, suggesting potential efficacy for a muscle disorder that typically robs patients of muscle control and strength beginning around adolescence. While PepGen claims the data are promising, the study is still in early stages and does not yet confirm long-term outcomes or definitive treatment success.

Key points

• PepGen's experimental drug showed the most promising early data in the race to treat myotonic dystrophy type 1 (DM1), affecting over 100,000 people in the U.S. and Europe.
• Six patients were treated for 12 weeks, with results indicating potential efficacy for a muscle disorder that typically robs patients of muscle control and strength beginning around adolescence.

Context

PepGen's findings come as a race to treat myotonic dystrophy type 1 (DM1) intensifies, with Dyne Therapeutics nearing completion of a pivotal trial and Novartis failing a Phase 3 trial for a DM1 drug acquired in its $12 billion buyout of Avidity Biosciences.

Limitations

The evidence is limited to six patients treated for 12 weeks, and the study does not yet confirm long-term outcomes or definitive treatment success. The data are preliminary and do not constitute a final conclusion on the drug's efficacy for DM1.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 10/11/2026, 12:08:01 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeign6zo4ghdappcf2lpxebuxn7qd4m2vpmpzs3qz3r2qabfmruaidy